In response to a burgeoning outbreak of meningococcal meningitis, U.K. health officials are swiftly implementing an extensive antibiotic and vaccination drive to manage the situation, particularly among the student population.
Initially identified at the University of Kent, this highly contagious bacterial infection has rapidly spread throughout the region. By March 19, health authorities had reached out to thousands of individuals potentially exposed to the disease. The U.K. Health Security Agency reported that there were at least 29 confirmed or suspected cases, with two resulting in fatalities.
Antibiotic treatment, administered before symptoms arise, can effectively control bacterial meningitis outbreaks. However, experts emphasize that routine vaccination is crucial for high-risk groups, especially young adults in communal settings like college campuses, to prevent such outbreaks.
On supporting science journalism
If you’re enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription, you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
“This outbreak is a very unusual event,” remarks William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center. For context, the U.K. recorded 378 confirmed cases of the illness between July 2024 and June 2025, while the U.S. reported 503 confirmed and probable cases in 2024. “It’s very impressive that our comprehensive vaccination programs in the United States and in the U.K. have reduced the occurrence of this very frightening disease very substantially in our populations,” he says.
Despite the success of these vaccines, recent actions by the Trump administration have raised concerns in the U.S. In January, the Centers for Disease Control and Prevention reversed its recommendation for universal childhood vaccination against meningococcal meningitis. However, a U.S. district court has temporarily halted this change. The Department of Health and Human Services, overseeing the CDC, did not respond to Scientific American’s inquiries about the current vaccine guidelines.
Scientific American consulted infectious disease experts to discuss the risks associated with bacterial meningitis and the protective role of vaccination.
What is bacterial meningitis?
Meningitis involves the inflammation of the meninges, membranes encasing the brain and spinal cord. Causes include bacteria, fungi, viruses, and autoimmune disorders, as explained by Nicholas Van Sickels, medical director of infection prevention at University of Kentucky HealthCare.
“In an outbreak setting, though, what we’re typically talking about is bacterial meningitis,” he notes. “You often hear about it in situations like what’s going on in England, where you have a college campus and often very healthy individuals present as very, very sick in a short period of time—and some die.”
Bacterial meningitis is usually triggered by meningococcal disease, which is caused by the bacterium Neisseria meningitidis. This bacterium spreads via aerosolized droplets and close contact, making it highly contagious in confined spaces like dormitories or military quarters. Early symptoms include fever, headache, rapid breathing, and chills, possibly progressing to a distinctive rash that resists pressure. The condition can swiftly worsen, affecting the cerebral spinal fluid and brain. Schaffner explains, “The patient can get drowsy and even delirious and then lapse into a coma.”
This bacterium can also enter the bloodstream, causing inflammation in blood vessels and potentially leaving sufferers with long-term complications.
“Even if the infection is well treated, there’s so much inflammation that they can have long-term disabilities as a consequence,” Schaffner says. “Some people have hearing difficulties. Sometimes you get gangrene, and amputations become necessary.”
How is bacterial meningitis treated or prevented?
According to Schaffner, antibiotics are effective against bacterial meningitis if administered promptly. In the U.K., health authorities are distributing thousands of antibiotic doses as an immediate measure to students at risk. Schaffner believes this strategy “should bring this outbreak to a close.” He stresses that vaccination remains critical for preventing future outbreaks.
Both the U.K. and the U.S. offer two types of meningococcal vaccines: MenACWY and MenB. These vaccines target different strains of N. meningitidis. Strains A, C, W, and Y are more prevalent than strain B.
In the U.K., the MenACWY vaccine is advised for teenagers around 14 years old. Additionally, health authorities recommend that infants receive the MenB vaccine at eight weeks, with follow-up doses at 12 weeks and a year. The outbreak in Kent was linked to the less common B strain, prompting a focused MenB vaccination initiative for Kent area students alongside antibiotic distribution.
In the U.S., meningococcal disease cases have been increasing since 2021, with a notable rise in strain Y cases, as reported by the CDC. Currently, it is recommended that immunocompromised children aged 16 and above receive the MenB vaccine, while others in this age group can opt for it through shared clinical decision-making.
Due to the rarity of B strains, the vaccine is optional, but Schaffner notes that “more and more parents are having their children vaccinated against meningitis B, particularly before they go to college, because they don’t want to be in a circumstance where there is easy transmission of this bug.”
Previously, the CDC recommended two doses of the MenACWY for all children—the first between ages 11 and 12, and a booster at 16. However, in January, the agency amended this to allow the MenACWY vaccine to be optional for most children, a move contested in legal proceedings.
Van Sickels states that both MenB and MenACWY vaccines are safe and effective, providing highest protection within five years post-MenACWY vaccination and one to two years after MenB vaccination. Proper timing is crucial to ensure peak immunity when children are most vulnerable, he adds. Some U.S. colleges mandate both vaccines for students residing in dormitories, and the MenACWY vaccine is required for military personnel.
Schaffner concludes, “Our national vaccination campaign with the [four-strain MenACWY vaccine] has been a brilliant success. It’s another example of how routine, comprehensive vaccination has had a profound effect on really dramatically reducing the occurrence of what was once an extreme, ordinarily feared infection.”
